These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 29478674)

  • 21. Induced mutation and epigenetics modification in plants for crop improvement by targeting CRISPR/Cas9 technology.
    Khan MHU; Khan SU; Muhammad A; Hu L; Yang Y; Fan C
    J Cell Physiol; 2018 Jun; 233(6):4578-4594. PubMed ID: 29194606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR/Cas9-mediated somatic correction of a novel coagulator factor IX gene mutation ameliorates hemophilia in mouse.
    Guan Y; Ma Y; Li Q; Sun Z; Ma L; Wu L; Wang L; Zeng L; Shao Y; Chen Y; Ma N; Lu W; Hu K; Han H; Yu Y; Huang Y; Liu M; Li D
    EMBO Mol Med; 2016 May; 8(5):477-88. PubMed ID: 26964564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CRISPR/Cas9 in cancer therapy: A review with a special focus on tumor angiogenesis.
    Hariprabu KNG; Sathya M; Vimalraj S
    Int J Biol Macromol; 2021 Dec; 192():913-930. PubMed ID: 34655593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting mutant TP53 as a potential therapeutic strategy for the treatment of osteosarcoma.
    Tang F; Min L; Seebacher NA; Li X; Zhou Y; Hornicek FJ; Wei Y; Tu C; Duan Z
    J Orthop Res; 2019 Mar; 37(3):789-798. PubMed ID: 30667081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research Progress on Nanoparticles-Based CRISPR/Cas9 System for Targeted Therapy of Tumors.
    Nie D; Guo T; Yue M; Li W; Zong X; Zhu Y; Huang J; Lin M
    Biomolecules; 2022 Sep; 12(9):. PubMed ID: 36139078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
    Luo J
    Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
    [No Abstract]   [Full Text] [Related]  

  • 28. CRISPR-cas System as a Genome Engineering Platform: Applications in Biomedicine and Biotechnology.
    Hashemi A
    Curr Gene Ther; 2018; 18(2):115-124. PubMed ID: 29473500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CRISPR-Cas9 technology and its application in haematological disorders.
    Zhang H; McCarty N
    Br J Haematol; 2016 Oct; 175(2):208-225. PubMed ID: 27619566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia B using the CRISPR-Cas9 system.
    Lyu C; Shen J; Wang R; Gu H; Zhang J; Xue F; Liu X; Liu W; Fu R; Zhang L; Li H; Zhang X; Cheng T; Yang R; Zhang L
    Stem Cell Res Ther; 2018 Apr; 9(1):92. PubMed ID: 29625575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR-Cas9: from Genome Editing to Cancer Research.
    Chen S; Sun H; Miao K; Deng CX
    Int J Biol Sci; 2016; 12(12):1427-1436. PubMed ID: 27994508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CRISPR/Cas9 Gene Editing: From Basic Mechanisms to Improved Strategies for Enhanced Genome Engineering In Vivo.
    Salsman J; Masson JY; Orthwein A; Dellaire G
    Curr Gene Ther; 2017; 17(4):263-274. PubMed ID: 29173169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CRISPR/Cas9 therapeutics for liver diseases.
    Aravalli RN; Steer CJ
    J Cell Biochem; 2018 Jun; 119(6):4265-4278. PubMed ID: 29266637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CRISPR/Cas9 genome engineering in hematopoietic cells.
    Sürün D; von Melchner H; Schnütgen F
    Drug Discov Today Technol; 2018 Aug; 28():33-39. PubMed ID: 30205879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3.
    Batır MB; Şahin E; Çam FS
    Mol Biol Rep; 2019 Dec; 46(6):6471-6484. PubMed ID: 31571107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells.
    Kim EJ; Kang KH; Ju JH
    Korean J Intern Med; 2017 Jan; 32(1):42-61. PubMed ID: 28049282
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation of NERCe003-A-3, a p53 compound heterozygous mutation human embryonic stem cell line, by CRISPR/Cas9 editing.
    Li Y; Huang C; Zha L; Kong M; Yang Q; Zhu Y; Peng Y; Ouyang Q; Lu G; Lin G; Zhou D
    Stem Cell Res; 2019 Jan; 34():101371. PubMed ID: 30658254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CRISPR/Cas9, the Powerful New Genome-Editing Tool for Putative Therapeutics in Obesity.
    Franco-Tormo MJ; Salas-Crisostomo M; Rocha NB; Budde H; Machado S; Murillo-Rodríguez E
    J Mol Neurosci; 2018 May; 65(1):10-16. PubMed ID: 29732484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
    Hou J; Cao X; Cheng Y; Wang X
    Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.